Log In
Print
BCIQ
Print
Print this Print this
 

HLD-200

  Manage Alerts
Collapse Summary General Information
Company Highland Therapeutics Inc.
DescriptionModified-release formulation of the generic methylphenidate
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase III
Standard IndicationAttention deficit hyperactivity disorder (ADHD)
Indication DetailsTreat ADHD
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today